Financial Characteristics of Outcomes-Based Agreements: What Do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?

20sense’s most recent peer-reviewed publication entitled “Financial Characteristics of Outcomes-Based Agreements (OBAs): What do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?” highlights public payers’ preference for short-term OBAs and manufacturers’ openness to a wider range of OBA durations.

Additionally, the paper identifies six key success factors of acceptable OBAs for both payers and manufacturers, including interim reporting, easily measurable health outcomes, trusted data sources, engaging unbiased third-party data experts, harmonizing OBA billing methods, and the inclusion of budget caps.

The RHC is excited to share this publication because understanding the preferences of key stakeholders – such as payers and manufacturers – and identifying factors that are instrumental to the success of OBAs are the fundamental steps to designing effective OBAs that will ultimately improve patient health outcomes.

To access the full publication, click here.